NASCOTCWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Can B Corp
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$0.01−0.00 (-1.32%)
Close on Oct 19, 2026
- Market cap
- $981.54K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2023
Gross margin
16.6%−22.7 pts over 5 years
Operating margin
-347.3%+163.6 pts over 5 years
Net margin
-451.7%+163.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -67.8% | +8.0% | +26.4% | – | |
| Gross profit | -86.3% | -37.0% | +6.4% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2018 | FY2023 | Trend |
|---|---|---|---|---|
| Return on equity | – | -467.6% | -2317.5% | |
| Return on assets | – | -210.2% | -75.8% | |
| Current ratio | 1.06 | 5.59 | 0.45 | |
| Interest coverage | – | -13.0× | -3.0× | |
| Inventory turnover | – | 8.4× | 1.0× | |
| Capex to revenue | – | 6.9% | 0.7% | |
| Diluted shares | – | 0M | 13M |
Cash use needs five years of cash flow figures
Can B does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-451.7%
×Asset turnover0.17×
×Equity multiplier30.57×
=Return on equity, FY2023-2317.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -451.7% | 0.17× | 30.57× | -2317.5% |
| FY2022 | -223.2% | 0.42× | 3.85× | -358.9% |
| FY2021 | -264.3% | 0.45× | 2.87× | -343.0% |
| FY2020 | -519.3% | 0.31× | 1.37× | -218.5% |
| FY2019 | -255.9% | 0.42× | 1.08× | -116.4% |
| FY2018 | -615.1% | 0.34× | 2.22× | -467.6% |
| FY2017 | -1743.2% | 0.69× | -0.16× | 190.7% |
| FY2016 | -699.0% | 0.60× | -0.77× | 323.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
2of 8 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero-$9.74M
- Cash generatingOperating cash flow above zero-$1.30M
- Return on assets improvedROA up on the prior year-90.6% → -62.6%
- Earnings backed by cashOperating cash flow above net income-$1.30M vs -$9.74M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.70 → 0.45
- No dilutionShare count did not rise4M → 13M
- Gross margin improvedGross margin up on the prior year39.11% → 16.64%
- More efficientAsset turnover rose0.41 → 0.14